uniQure N.V. (NASDAQ:QURE) Director Jeremy P. Springhorn Sells 2,112 Shares

uniQure N.V. (NASDAQ:QURE) Director Jeremy P. Springhorn sold 2,112 shares of the business’s stock in a transaction on Friday, June 20th. The shares were sold at an average price of $14.45, for a total transaction of $30,518.40. Following the sale, the director now owns 37,694 shares in the company, valued at approximately $544,678.30. This trade represents a 5.31% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

uniQure Price Performance

QURE opened at $14.22 on Wednesday. The company’s 50-day simple moving average is $14.38 and its two-hundred day simple moving average is $13.99. The company has a debt-to-equity ratio of 1.53, a quick ratio of 11.99 and a current ratio of 11.99. The stock has a market capitalization of $778.97 million, a P/E ratio of -3.24 and a beta of 0.08. uniQure N.V. has a 52-week low of $3.73 and a 52-week high of $19.18.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.25. uniQure had a negative net margin of 1,077.05% and a negative return on equity of 483.87%. The firm had revenue of $1.57 million during the quarter, compared to analysts’ expectations of $5.93 million. As a group, analysts predict that uniQure N.V. will post -3.75 EPS for the current year.

Hedge Funds Weigh In On uniQure

Hedge funds and other institutional investors have recently modified their holdings of the company. Oppenheimer & Co. Inc. bought a new stake in shares of uniQure in the fourth quarter worth $320,000. Raymond James Financial Inc. purchased a new position in uniQure in the fourth quarter worth about $1,951,000. Monaco Asset Management SAM bought a new stake in shares of uniQure during the 4th quarter valued at about $2,414,000. Twin Tree Management LP purchased a new stake in shares of uniQure during the 4th quarter valued at about $77,000. Finally, JPMorgan Chase & Co. lifted its stake in shares of uniQure by 14.7% in the 4th quarter. JPMorgan Chase & Co. now owns 453,784 shares of the biotechnology company’s stock worth $8,014,000 after purchasing an additional 58,246 shares during the period. 78.83% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on QURE. Chardan Capital reiterated a “buy” rating and issued a $38.00 price target on shares of uniQure in a research note on Friday, May 30th. Wells Fargo & Company decreased their target price on shares of uniQure from $35.00 to $30.00 and set an “equal weight” rating for the company in a research note on Friday, February 28th. Cantor Fitzgerald upgraded shares of uniQure to a “strong-buy” rating in a report on Monday, May 19th. Wall Street Zen downgraded uniQure from a “hold” rating to a “sell” rating in a research note on Saturday, June 14th. Finally, Guggenheim reaffirmed a “buy” rating and set a $28.00 price objective on shares of uniQure in a research report on Monday, May 12th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, uniQure has an average rating of “Moderate Buy” and a consensus price target of $37.82.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.